



ASX and Media Release

12 June 2015

**ASCO PRESENTATION: RESULTS OF CAVATAK™ CALM
TRIAL IN MELANOMA
*Investor Conference Call***

	<u>US Eastern Time</u>	<u>UK time</u>	<u>Australian Eastern Standard Time</u>
Date:	June 16 2015	June 16 2015	June 17 2015
Time:	1:30pm	6:30pm	3:30am

Shareholders, investors and analysts are invited to join a teleconference featuring Dr Robert Andtbacka of the Huntsman Cancer Institute, Utah, and Lead Study Investigator on Viralytics' Phase 2 CALM trial in melanoma patients. Dr Andtbacka will step through the poster containing final results from the trial, which he presented at ASCO on June 1 (US time) – see Viralytics' ASX release dated June 2. Dr Andtbacka will be available to take questions. He will be joined on the call by Viralytics CEO Dr Malcolm McColl and CSO Dr Darren Shafren. The call will last about 45 minutes in total.

Details for joining the teleconference are as follows:

Conference ID: 5521 4883

Country	Date	Time	Dial In
USA Pacific Mountain Central Eastern	June 16 2015 June 16 2015 June 16 2015 June 16 2015	10:30am 11:30am 12:30pm 1:30pm	US Toll Free: 1855 293 1544
UK	June 16 2015	6:30pm	Toll Free 0808 234 0757
Australia (AEST)	June 17 2015	3:30am	Toll: +61 2 8038 5221 (can be used if dialing from international location) Toll-free: 1800 123 296

Please dial into the teleconference at least 10 minutes before the start of the presentation.

The teleconference will be recorded and a link provided on the Viralytics website.



About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:

Dr Malcolm McColl
Managing Director
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333